Dual Therapy for Complex Inflammatory Bowel Disease: Safety, Clinical and Steroid-Free Response
Anne-Mette Haase, Jens Kelsen, Jørgen Agnholt, Mia Bendix · 2026
Read Dual Therapy for Complex Inflammatory Bowel Disease: Safety, Clinical and Steroid-Free Response by Anne-Mette Haase, Jens Kelsen, Jørgen Agnholt, Mia Bendix (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13576839.txt.
Description
Haase, Kelsen, Agnholt, and Bendix reviewed dual therapy for complex inflammatory bowel disease in twenty twenty-six. Single advanced drugs bring remission in only about thirty to fifty percent of patients in the first year. Dual therapy pairs two advanced drugs for patients whose bowel inflammation or symptoms elsewhere persist.
The team reviewed records from two Danish hospitals for patients treated at least three months between twenty eighteen and twenty twenty-three. Seventy-four patients received seventy-nine dual therapies, most often Crohn's disease cases. About half achieved a clinical response by follow-up. Most Crohn's patients reached follow-up free of steroids. Severe side effects occurred in eight therapies. The authors call the response rate substantial but say the risk must be weighed against the gain.
Catalog record
| CREATOR | Anne-Mette Haase, Jens Kelsen, Jørgen Agnholt, Mia Bendix |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |